The primary purpose of the clinical trial is to investigate safety and tolerability of escalating doses of OBI-833/OBI-821 in subjects with metastatic incurable solid tumors, such as gastric, lung,colorectal or breast cancer. Meanwhile, the tumor response and humoral immune responses, i.e.,anti-Globo H IgG and IgM production following administration of OBI-833/OBI-821 will be assessed as the secondary objective of this study.